<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01455922</url>
  </required_header>
  <id_info>
    <org_study_id>ITCA 650-CLP-112</org_study_id>
    <nct_id>NCT01455922</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes</brief_title>
  <official_title>A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intarcia Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intarcia Therapeutics</source>
  <brief_summary>
    <textblock>
      Phase 3 study to examine treatment with ITCA 650 compared to glimepiride when added to
      metformin monotherapy in reducing HbA1c in patients with type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>52 weeks</time_frame>
    <description>52-week Treatment Period followed by 52-week Extension Period</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>ITCA 650 60 mcg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>glimepiride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ITCA 650</intervention_name>
    <description>ITCA 650 is exenatide in DUROS</description>
    <arm_group_label>ITCA 650 60 mcg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glimepiride</intervention_name>
    <description>glimepiride will be up-titrated to 8 mg/day over first 13 weeks</description>
    <arm_group_label>glimepiride</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HbA1c between 7.5% - 10.5%

          -  on metformin monotherapy

          -  BMI between 25 &amp; 45 kg/m2

        Exclusion Criteria:

          -  On thiazolidinedione, sulfonylurea, DPP-4, alpha glucosidase inhibitor, meglitinides
             or insulin within last 3 months

          -  history of pancreatitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Intarcia Therapeutics, Inc</name>
      <address>
        <city>Hayward</city>
        <state>California</state>
        <zip>94545</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2011</study_first_submitted>
  <study_first_submitted_qc>October 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2011</study_first_posted>
  <last_update_submitted>December 21, 2012</last_update_submitted>
  <last_update_submitted_qc>December 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

